DalCor Pharmaceuticals is a biopharmaceutical company focused on addressing cardiovascular disease, the greatest global healthcare burden. Our purpose is to deliver dalcetrapib, the first pharmacogenetic precision medicine in cardiovascular disease that specifically targets patients with the AA genotype at rs1967309 location in the ADCY9 gene (ADCY9 AA genotype)...
DalCor is developing dalcetrapib, a precision pharmacogenetic medicine for patients with a heart attack to reduce the risk of recurrent myocardial infarction.